Condition

ADHF

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials7

Recruiting3

Common interventions6

Lead sponsors shown7

Clinical trials

7 shown

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart FailureNCT05677100 · 2023-08-23

RECRUITING

Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF)NCT06169540 · 2023-04-19

RECRUITING

Care Coordination to Assess Improvement in Outcomes in Hospital ReadmissionsNCT04905160 · 2021-02-18

RECRUITING

Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital ReadmissionsNCT02003040 · 2014-09-01

UNKNOWN

3-dimensional Sensor Technology to Quantify Leg-edemaNCT01700023 · 2012-09-01

UNKNOWN

Troponin I Release After High Diuretic DosesNCT01419132 · 2011-08-01

COMPLETED

PK/PD Study of Subcutaneous Cenderitide Infusion in CHF PatientsNCT01316432 · 2011-05-01

COMPLETED

Common interventions

Aortix SystemDEVICE1 CenderitideDRUG1 COMPASSION Digital BiomarkerOTHER1 FurosemideDRUG1 Mespere Venus 1000 CVP SystemDEVICE1 PlaceboOTHER1

Leading sponsors

Aventyn, Inc. 1 Massachusetts General Hospital 1 Medical University of Graz 1 Mespere Lifesciences Inc. 1 Nile Therapeutics 1 Procyrion 1 University of Palermo 1

Trial status mix

RECRUITING3

COMPLETED2

UNKNOWN2

Phase mix

NA2

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.